Unusual presentation of congenital disorder of glycosylation type 1a: congenital persistent thrombocytopenia, hypertrophic cardiomyopathy and hydrops-like aspect due to marked peripheral oedema

2005 ◽  
Vol 164 (4) ◽  
pp. 223-226 ◽  
Author(s):  
Vera Noelle ◽  
Matthias Knuepfer ◽  
Ferdinand Pulzer ◽  
Volker Schuster ◽  
Werner Siekmeyer ◽  
...  
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Congenital Disorder ◽  
Unusual Presentation ◽  
Peripheral Oedema ◽  
Congenital Disorder Of Glycosylation ◽  
Persistent Thrombocytopenia

Severe transient myocardial ischaemia caused by hypertrophic cardiomyopathy in a patient with congenital disorder of glycosylation type Ia

2002 ◽  
Vol 161 (10) ◽  
pp. 524-527 ◽  
Author(s):  
Thorsten Marquardt ◽  
Georg Hülskamp ◽  
Josef Gehrmann ◽  
Volker Debus ◽  
Erik Harms ◽  
...  
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Myocardial Ischaemia ◽  
Congenital Disorder ◽  
Congenital Disorder Of Glycosylation ◽  
Type Ia

Hypertrophic Cardiomyopathy With Cardiac Rupture and Tamponade Caused by Congenital Disorder of Glycosylation Type Ia

2012 ◽  
Vol 33 (5) ◽  
pp. 827-830 ◽  
Author(s):  
Laura I. Rudaks ◽  
Chad Andersen ◽  
T. Y. Khong ◽  
Andrew Kelly ◽  
Michael Fietz ◽  
...  
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Congenital Disorder ◽  
Cardiac Rupture ◽  
Congenital Disorder Of Glycosylation ◽  
Type Ia

Functional analysis of three splicing mutations identified in the PMM2 gene: Toward a new therapy for congenital disorder of glycosylation type Ia

2009 ◽  
Vol 30 (5) ◽  
pp. 795-803 ◽  
Author(s):  
Ana I. Vega ◽  
Celia Pérez-Cerdá ◽  
Lourdes R. Desviat ◽  
Gert Matthijs ◽  
Magdalena Ugarte ◽  
...  
Keyword(s):  
Functional Analysis ◽  
Congenital Disorder ◽  
Congenital Disorder Of Glycosylation ◽  
New Therapy ◽  
Splicing Mutations ◽  
Type Ia

Skeletal Dysplasia and Myelopathy in Congenital Disorder of Glycosylation Type IA

2006 ◽  
Vol 148 (1) ◽  
pp. 115-117 ◽  
Author(s):  
Steven M. Schade van Westrum ◽  
Paul J. Nederkoorn ◽  
P. Richard Schuurman ◽  
Tom Vulsma ◽  
Marinus Duran ◽  
...  
Keyword(s):  
Skeletal Dysplasia ◽  
Congenital Disorder ◽  
Congenital Disorder Of Glycosylation ◽  
Type Ia

scholarly journals Bi-allelic variants in the ER quality control mannosidase gene EDEM3 cause a congenital disorder of glycosylation

2021 ◽  
Author(s):  
Daniel L. Polla ◽  
Andrew C. Edmondson ◽  
Sandrine Duvet ◽  
Michael E. March ◽  
Ana Berta Sousa ◽  
...  
Keyword(s):  
Quality Control ◽  
Congenital Disorder ◽  
Er Quality Control ◽  
Allelic Variants ◽  
Congenital Disorder Of Glycosylation

scholarly journals Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG

2019 ◽  
Author(s):  
Sangeetha Iyer ◽  
Feba S. Sam ◽  
Nina DiPrimio ◽  
Graeme Preston ◽  
Jan Verhejein ◽  
...  
Keyword(s):  
Enzyme Activity ◽  
Diabetic Neuropathy ◽  
Aldose Reductase ◽  
Reductase Inhibitor ◽  
Drug Repurposing ◽  
Polyol Pathway ◽  
Aldose Reductase Inhibitor ◽  
Congenital Disorder ◽  
Functional Studies ◽  
Congenital Disorder Of Glycosylation

AbstractPhosphomannomutase 2 deficiency, or PMM2-CDG, is the most common congenital disorder of glycosylation affecting over 1,000 patients globally. There are no approved drugs that treat the symptoms or root cause of PMM2-CDG. In order to identify clinically actionable compounds that boost human PMM2 enzyme function, we performed a multi-species drug repurposing screen using a first-ever worm model of PMM2-CDG followed by PMM2 enzyme functional studies in PMM2-CDG patient fibroblasts. Drug repurposing candidates from this study, and drug repurposing candidates from a previously published study using yeast models of PMM2-CDG, were tested for their effect on human PMM2 enzyme activity in PMM2-CDG fibroblasts. Of the 20 repurposing candidates discovered in the worm-based phenotypic screen, 12 are plant-based polyphenols. Insights from structure-activity relationships revealed epalrestat, the only antidiabetic aldose reductase inhibitor approved for use in humans, as a first-in-class PMM2 enzyme activator. Epalrestat increased PMM2 enzymatic activity in four PMM2-CDG patient fibroblast lines with genotypes R141H/F119L, R141H/E139K, R141H/N216I and R141H/F183S. PMM2 enzyme activity gains range from 30% to 400% over baseline depending on genotype. Pharmacological inhibition of aldose reductase by epalrestat may shunt glucose from the polyol pathway to glucose-1,6-bisphosphate, which is an endogenous stabilizer and coactivator of PMM2 homodimerization. Epalrestat is a safe, oral and brain penetrant drug that was approved 27 years ago in Japan to treat diabetic neuropathy in geriatric populations. We demonstrate that epalrestat is the first small molecule activator of PMM2 enzyme activity with the potential to treat peripheral neuropathy and correct the underlying enzyme deficiency in a majority of pediatric and adult PMM2-CDG patients.

scholarly journals Congenital disorder of glycosylation type Ia: a non-progressive encephalopathy associated with multisystemic involvement

2008 ◽  
Vol 66 (3a) ◽  
pp. 545-548 ◽  
Author(s):  
Jaime Moritz Brum ◽  
Isabela Maria Pinto de Oliveira Rizzo ◽  
Walquiria Domingues de Mello ◽  
Carlos Eduardo Speck-Martins
Keyword(s):  
Congenital Disorder ◽  
Congenital Disorder Of Glycosylation ◽  
Progressive Encephalopathy ◽  
Type Ia
Sign in / Sign up

Export Citation Format

Share Document